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PLATE-BREAKING CLINICAL TRIAL
Clinical Effectiveness of
Coronary Stents in Elderly Persons
Results From 262,700 Medicare Patients in the American College
of Cardiology–National Cardiovascular Data Registry
Pamela S. Douglas, MD,* J. Matthew Brennan, MD,* Kevin J. Anstrom, PHD,*
Art Sedrakyan, MD, PHD,† Eric L. Eisenstein, DBA,* Ghazala Haque, MBBS, MHS,*
David Dai, PHD,* David F. Kong, MD,* Bradley Hammill, PHD,* Lesley Curtis, PHD,*
David Matchar, MD,* Ralph Brindis, MD,‡§ Eric D. Peterson, MD, MPH*
Durham, North Carolina; Rockville, Maryland; Oakland, California; and Washington, DC
Objectives The aim of this study was to compare outcomes in older individuals receiving drug-eluting stents (DES) and bare-
metal stents (BMS).
Background Comparative effectiveness of DES relative to BMS remains unclear.
Methods Outcomes were evaluated in 262,700 patients from 650 National Cardiovascular Data Registry sites during
2004 to 2006 with procedural registry data linked to Medicare claims for follow-up. Outcomes including death,
myocardial infarction (MI), revascularization, major bleeding, stroke, death or MI, death or MI or revasculariza-
tion, and death or MI or stroke were compared with estimated cumulative incidence rates with inverse probabil-
ity weighted estimators and Cox proportional hazards ratios.
Results The DES were implanted in 217,675 patients and BMS were implanted in 45,025. At 30 months, DES patients
had lower unadjusted rates of death (12.9% vs. 17.9%), MI (7.3 of 100 patients vs. 10.0 of 100 patients), and
revascularization (23.0 of 100 patients vs. 24.5 of 100 patients) with no difference in stroke or bleeding. After
adjustment, DES patients had lower rates of death (13.5% vs. 16.5%, hazard ratio [HR]: 0.75, 95% confidence
interval [CI]: 0.72 to 0.79, p  0.001) and MI (7.5 of 100 patients vs. 8.9 of 100 patients, HR: 0.77, 95% CI:
0.72 to 0.81, p  0.001), with minimal difference in revascularization (23.5 of 100 patients vs. 23.4 of 100 pa-
tients; HR: 0.91, 95% CI: 0.87 to 0.96), stroke (3.1 of 100 patients vs. 2.7 of 100 patients, HR: 0.97, 95% CI:
0.88 to 1.07), or bleeding (3.4 of 100 patients vs. 3.6 of 100 patients, HR: 0.91, 95% CI: 0.84 to 1.00). The DES
survival benefit was observed in all subgroups analyzed and persisted throughout 30 months of follow-up.
Conclusions In this largest ever real-world study, patients receiving DES had significantly better clinical outcomes than their
BMS counterparts, without an associated increase in bleeding or stroke, throughout 30 months of follow-up and
across all pre-specified subgroups. (J Am Coll Cardiol 2009;53:1629–41) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.005c
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Effectiveness of Coronary Stents May 5, 2009:1629–41and Drug Administration (FDA)
advisories in 2006 (7,8) as well as
subsequent studies refining event
rates (1,6,9–13). The rarity of
late DES complications means
that extremely large sample sizes
are required to clarify their fre-
quency. Furthermore, the ability
to examine rates of lower fre-
quency complications in impor-
tant patient subgroups is limited
in smaller sample sizes (14).
Accordingly, the Agency for
Healthcare Research and Qual-
ity and the U.S. FDA commis-
sioned the formation of a na-
tionally representative percuta-
neous coronary intervention (PCI)
database to determine the safety
and effectiveness of DES and
BMS among a contemporary
“real-world” cohort. This was ac-
complished through linkage of the
American College of Cardiology–
National Cardiovascular Data
Registry (ACC-NCDR) with the
Centers for Medicare and Medic-
aid Services national claims data-
base. The resulting analyses will
etter inform national practice patterns overall and in impor-
ant patient and lesion-level subgroups.
ethods
tudy population. The national ACC-NCDR CathPCI
egistry collects information for patients undergoing PCI
rocedures. We included all CathPCI patients 65 years of
ge undergoing an inpatient intracoronary stent procedure
etween January 1, 2004, and December 31, 2006. Patients
eceiving more than 1 stent type (i.e., both BMS and DES)
ere excluded (Fig. 1). The Duke University Medical
enter Institutional Review Board granted a waiver of
nformed consent and authorization for this study.
ollow-up information. Because ACC-NCDR data are
imited to a single episode of care we used the research-
dentifiable Medicare 100% inpatient fee-for-service claims
le for longitudinal patient follow-up. The PCI procedure
odes (International Classification of Diseases-Ninth
evision-Clinical Modification [ICD-9-CM] procedure
odes: 00.66, 36.0x, 37.22, 37.23, and 88.5x, except 88.59)
ere used to identify potential index procedure matches in
he Medicare files, which were then linked to NCDR with
ndirect identifiers (nonunique fields that when used in
ombination might identify unique hospital stays) to create
nidentified longitudinal profiles and obtain up to 3 years’
Abbreviations
and Acronyms
ACC  American College of
Cardiology
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
HR  hazard ratio
IPW  inverse propensity
weighted scoring
MI  myocardial infarction
NCDR  National
Cardiovascular Data
Registry
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
RCT  randomized
controlled trial
STEMI  ST-segment
elevation myocardial
infarctionollow-up. Linking rules used a hierarchy of evidence ppproach such that rules with the most information were
pplied before those with less information. Once a match
as achieved for a patient, no further rules were applied.
ur linking rules contained combinations of information
enoting the index PCI procedure site, patient date of birth
or components thereof) or age, admission date, discharge
ate, and sex. In the rare event that a single ACC-NCDR
ecord could be matched with multiple Medicare records
ith the same rule, no linking occurred. Sites that did not
atch to Medicare records were excluded, as were patients
hose index PCI procedure did not occur during a period of
ee-for-service enrollment.
linical end points. We evaluated 8 clinical end points: 5
vents and 3 composites. Death was the only event defined
oth during the index PCI procedure (with ACC-NCDR
nformation) and after discharge (with the Medicare de-
ominator file). Clinical end points were defined with the
edicare claims file as the primary diagnosis for a hospital
dmission. The ICD-9-CM diagnosis codes used to iden-
ify events were: myocardial infarction (MI) (410.X1),
troke (430.X, 431.X, 432.X, 434.X), and bleeding (430-
32, 578.X, 719.1X, 423.0, 599.7, 626.2, 626.6, 626.8,
27.0, 627.1, 786.3, 784.7, or 459.0). Revascularizations
ere identified with ICD-9-CM procedure codes (PCI:
6.00, 36.06, 36.07, 36.09; coronary artery bypass grafting
CABG]: 36.10-19). Only revascularizations occurring after
ischarge from the index hospital stay were included in the
evascularization analysis. The composite events used in this
tudy were: MI or death, MI or death or revascularization,
nd MI or death or stroke.
tatistical analysis. Baseline and propensity matching
haracteristics were categorized by stent type (DES vs.
MS) and summarized as counts and percentages for
ategorical variables and mean with standard deviations for
ontinuous variables. Statistical significance was defined
s p  0.05, with no correction for multiple comparisons,
ith SAS statistical software (version 9.1, SAS Institute,
ary, North Carolina) for all calculations.
ropensity score models. We used propensity scores to
djust for between-treatment group differences in baseline
haracteristics (15). Propensity scores represent the esti-
ated probabilities of patients receiving DES versus BMS
n our population (15), in this case conditioned upon 102
bserved covariates (Online Table). Inverse probability
eighted (IPW) estimators incorporating propensity scores
ere used to compare treatment groups (16). The propen-
ity score model had a c-index of 0.690. In addition, the
istribution of propensity scores for DES patients closely
atch those for BMS patients as evidenced by the
-number summaries (min, 25th, 50th, 75th, max) describ-
ng the curves for patients receiving each type of stent: BMS
14.5%, 70.7%, 79.6%, 85.9%, and 99.1%) and DES
16.0%, 79.7%, 86.1%, 90.7%, and 99.5%). The overlap
etween the groups is excellent and suggests that the
ropensity score approach is statistically appropriate.
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May 5, 2009:1629–41 Effectiveness of Coronary StentsInverse probability weighted estimators with monthly
ata partitions were used to calculate cumulative incidence
ates for clinical end points (adjusted and unadjusted)
17,18). Unadjusted estimates were based upon Kaplan-
eier estimates for treatment-specific censoring distribu-
ions, whereas adjusted estimates were based upon weights
hat were functions of Kaplan-Meier censoring estimates
nd propensity score estimates (17,18). Adjusted hazard
atios (HRs) were calculated according to the IPW ap-
roach of Cole and Hernan (19). In particular, we calculated
IPW Cox proportional hazards models—1 with an indi-
ator for DES as the only covariate and 1 with DES plus a
elected group of clinically important variables including:
ex, age, diabetes, renal disease, prior revascularization, prior
All A
1,878,183 PCI adm
Exclude patients without stent 
application.
Index 
CMS NOT Matched 
97,411 PCI admissions, 653 sites, 97,411 patients 
After exclExclude five sites that do not match CMS 
(id # 104827, 120617, 249450, 802687, 917494)
Exclude the admissions other than the index 
PCI stent application for each patient
A
Total PCI admissions for 
or after 2004 a
480,772 PCI adm
Exclude patients whose index stent application was 
not during Fee-For-Service (FFS) enrollment 
14,225 PCI admissions, 597 sites, 14,225 patients 
Exclude admissions with both DES and BMS 
12,822 PCI admissions, 583 sites, 12,822 patients 
Exclude records with missing candidate variables and
time-to-censor out of range [0-1096 days]
Figure 1 Population Selection: Flow Diagram
ACC  American College of Cardiology; BMS  bare-metal stent(s); CMS  Cente
and Medicaid Services; DES  drug-eluting stent(s); NCDR  National CardiovascI, multivessel coronary artery disease, year of procedures, and race. From these models, we estimated the adjusted HR
or DES versus BMS along with a 95% confidence interval
CI) on the basis of the sandwich estimated standard errors.
o visually assess the proportional treatment effect assump-
ions, we plotted the monthly cumulative incidence rates
ver the 30-month follow-up period. Additionally, we
lotted the treatment-group specific cumulative incidence
ates excluding events from the first 6 and 12 months to
dentify the long-term component of the treatment effect.
e refer to these latter analyses as 6- and 12-month
andmark analyses.
ox model. A Cox proportional hazards mortality model
without propensity score weighting) was developed with
ackward selection of the propensity score variables with
DR population
, 849 sites, 1,568,761 patients 
nt admissions for patients who had some stent application 
,973 PCI admissions, 662 sites, 390,973 patients 
CMS Matched 
290,438 PCI admissions, 650 sites, 290,438 patients 
ive sites that do not match CMS, the remaining population
49 PCI admissions, 657 sites, 387,849 patients  
dmissions for patients who had some stent application 
,242 PCI admissions, 662 sites, 390,973 patients 
s who were 65 or older, admitted in
harged in or before 2006
, 663 sites, 420,664 patients 
Patients whose index stent application was during
FFS enrollment 
276,213 PCI admissions, 650 sites, 276,213 patients 
Final study population 
262,700 PCI admissions, 650 sites, 262,700 patients
Admissions with either DES only or BMS only
263,391 PCI admissions, 650 sites, 263,391 patients 
edicare
ta Registry; PCI  percutaneous coronary intervention.CC-NC
issions
PCI ste
390
uding f
387,8
ll PCI a
450
patient
nd disc
issions
rs for M
ular Daselection threshold of p  0.05. Forward selection was
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Effectiveness of Coronary Stents May 5, 2009:1629–41nadjusted Baseline Characteristics of Patients in Study Population
Table 1 Unadjusted Baseline Characteristics of Patients in Study Population
Patient Characteristics
Study Population Study Population After Propensity Score Weighting
DES BMS
p Value
DES* BMS*
p Value(n  217,675) (n  45,025) (n  217,675) (n  45,025)
Age (mean  SD), yrs 74.5 6.4 75.3 6.7 0.001 74.7 74.8 0.03
Sex (male) 123,209 (56.6%) 27,024 (60.0) 0.001 57.2 57.0 NS
Race
Caucasian 196,260 (90.2%) 41,029 (91.1%) 0.001 90.3 90.2 NS
African American 9,051 (4.2%) 1,984 (4.4%) 0.017 4.2 4.3 NS
Asian 1,885 (0.9%) 254 (0.6%) 0.001 0.8 0.8 NS
Hispanic 3,843 (1.8%) 578 (1.3%) 0.001 1.7 1.7 NS
Other 6,258 (2.9) 1,092 (2.5%) 0.001 2.8 2.8 NS
Hospital region
Northeast 22,642 (10.4%) 5,371 (11.9%) 0.001 10.7 10.8 NS
South 80,612 (37.0%) 15,614 (34.7%) 0.001 36.6 36.8 NS
Midwest 83,956 (38.6%) 18,901 (41.9%) 0.001 39.1 39.0 NS
West 29,294 (13.5%) 4,874 (10.8%) 0.001 13.0 13.0 NS
Hospital setting
Rural 29,951 (13.8%) 6,756 (15.0%) 0.001 14.0 13.9 NS
Suburban 55,654 (25.6%) 12,658 (28.1%) 0.001 26.0 26.4 NS
Urban 132,070 (60.7%) 25,611 (56.9%) 0.001 60.0 59.8 NS
Year of index procedure
2004 58,453 (26.9%) 19,515 (43.3%) 0.001 29.7 30.3 NS
2005 74,685 (34.3%) 9,437 (21.0%) 0.001 32.0 31.2 NS
2006 84,537 (38.8%) 16,073 (35.7%) 0.001 38.3 38.5 NS
Mean follow-up (days  SD) 456.4 (302.5) 495.8 (371.4) 0.001 464.3 452.0 NS
Current smoking 25,955 (11.9%) 6,108 (13.6%) 0.001 12.2 12.3 NS
CHF 124,197 (57.1%) 23,112 (51.3%) 0.001 56.1 55.7 NS
HTN 175,154 (80.5%) 35,808 (79.5%) 0.001 80.3 80.6 NS
Renal failure
No dialysis 10,393 (4.8%) 2,701 (6.0%) 0.001 5.0 5.2 NS
Dialysis 3,380 (1.6%) 854(1.9%) 0.001 1.6 1.7 NS
Diabetes
Noninsulin-requiring 49,874 (22.9%) 9,930 (22.1%) 0.001 22.8 23.0 NS
Insulin 20,430 (9.4%) 4,533 (10.1%) 0.001 9.5 9.6 NS
Peripheral vascular disease 32,018 (14.7%) 7,776 (17.3%) 0.001 15.2 15.5 NS
Stroke 34,067 (15.7%) 7,908 (17.6%) 0.001 16.0 16.5 NS
Chronic lung disease 39,611 (18.2%) 9,163 (20.4%) 0.001 18.6 18.8 NS
Prior PCI 61,974 (28.5%) 11,678 (25.9%) 0.001 28.0 27.9 NS
Prior CABG 47,777 (22.0%) 12,735 (28.3%) 0.001 23.1 23.4 NS
Prior MI 57,282 (26.2%) 12,941 (28.7%) 0.001 26.8 26.9 NS
Urgency
Elective 111,426 (51.2%) 20,511 (45.6%) 0.001 50.2 49.6 NS
Urgent 82,296 (37.8%) 16,048 (35.6%) 0.001 37.4 37.8 NS
Emergent 23,616 (10.9%) 8,225 (18.3%) 0.001 12.1 12.4 NS
Indication
Stable angina 38,710 (17.8%) 6,129 (13.6%) 0.001 17.1 17.0 NS
UA/NSTEMI 34,581 (15.9%) 8,413 (18.7%) 0.001 51.3 51.0 NS
STEMI 21,170 (9.7%) 7,422 (16.5%) 0.001 10.9 11.1 NS
Pre-procedural shock 3,675 (1.7%) 1,746 (3.9%) 0.001 2.1 2.1 NS
Pre-procedural aspirin 144,296 (90.2%) 22,790 (88.8%) 0.001 64.3 62.6 NS
Pre-procedural clopidogrel 173,600 (80.2%) 35,821 (80.2%) 0.78 80.6 77.9 0.01
Pre-procedural IABP 637 (0.2%) 172 (0.4%) 0.001 0.3 0.3 NS
GP IIb/IIIa inhibitors 100,043 (46.1%) 21,726 (48.6%) 0.001 46.9 44.7 0.05
Multivessel PCI 34,185 (15.7%) 5,006 (11.1%) 0.001 14.9 14.6 NSContinued on next page
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May 5, 2009:1629–41 Effectiveness of Coronary Stentssed in a sensitivity analysis for internal validation of the
nal model, which contained 60 covariates. These models
erved to validate the adjusted HR estimates from the IPW
ox regression model method of Cole and Hernan (19).
ubgroup analyses. The PCI status included ST-segment
levation myocardial infarction (STEMI) (primary, rescue,
r facilitated), urgent (non–ST-segment elevation myocar-
ial infarction [NSTEMI] or unstable), and elective sub-
roups. Within the DES group, off- versus on-label use
ubgroups were examined. For patients enrolled in NCDR,
ith version 2 of the data collection form, off-label use was
efined as intervention on ACC/AHA Type C lesion, PCI
tatus of urgent or STEMI, intervention in a previously
reated lesion, use of more than 2 stents in a lesion,
reatment of a left main or graft segment, or multi-vessel
CI. For those enrolled using data collection form version
, the off-label use definition was modified to also include
evice diameter 2.5 or 4 mm, total stented or lesion
ength 30 mm, and bifurcation lesions.
ensitivity analyses. We conducted 2 sensitivity analyses.
or the first analysis, each of the 5 main outcomes were
xamined in a subgroup of patients fitting the inclusion and
xclusion criterion from the TAXUS IV (Treatment of de
ovo coronary disease using a single paclitAXel-elUting
tent IV) and SIRIUS (multicenter randomized double-
lind study of the SIRolImUS-coated Bx Velocity stent in
he treatment of patients with de novo coronary artery
esions) trials (n  49,355) (20,21) with a recalibrated
ropensity score including 76 clinical variables with a
-index of 0.71.
The second sensitivity analysis estimated “cause of death”
ontinued
Table 1 Continued
Patient Characteristics
Study Population
DES BMS
(n  217,675) (n  45,025)
Intervened vessels
LAD 96,278 (44.2%) 15,259 (33.9%)
LCX 66,766 (30.7%) 13,725 (30.5%)
RCA 83,508 (38.4%) 20,062 (44.6%)
Graft 17,412 (8.0%) 6,997 (15.5%)
Stents per patient, n
1 135,961 (62.5%) 30,833 (68.5%)
2 81,714 (37.5%) 14,192 (31.5%)
Vessels intervened, n
1 183,490 (84.3%) 40,019 (88.9%)
2 32,313 (14.8%) 4,754 (10.6%)
3 1,872 (0.9%) 252 (0.6%)
ACC/AHA type C lesions 83,853 (38.5%) 18,127 (40.3%)
Sirolimus-eluting (Cypher) 100,693 (46.3%)
Paclitaxel-eluting (Taxus) 120,320 (55.3%)
Off-label PCI 112,019 (69.2%)
Propensity-matched comparisons reported as % of the matched population.
ACC American College of Cardiology; AHA American Heart Association; BMS bare-metal s
tent(s); GP  glycoprotein; HTN  hypertension; IABP  intra-aortic balloon pump; LAD  left a
on–ST-segment elevation myocardial infarction; PCI  percutaneous coronary intervention; RCAfter stent implantation according to the primary diagnosis df a hospital stay during which the patient expired or the
ost recent hospital stay within 6 months of death. With a
reviously validated list of ICD-9 codes (22), we examined
he relative distribution of causes of death across DES and
MS patients.
esults
etween January 2004 and December 2006, 390,973
CDR patients 65 years of age underwent stent implan-
ation, and 76% were linked to longitudinal Medicare
ecords. After exclusions, the study population included
62,700 patients from 650 sites (Fig. 1). Comparison of
CDR patients who did and did not match to Medicare
ecords revealed nonmatch patients to be slightly younger
age 73 years vs. 74 years) and more likely to be men (62%
s. 58%) and to have commercial insurance (15% vs. 3%).
Overall, 45,025 patients received 1 or more BMS and
17,675 received 1 or more DES (54% paclitaxel-eluting,
6% sirolimus-eluting). Unadjusted baseline characteristics
how significant differences between DES and BMS; these
ifferences were reduced after propensity score weighting
Table 1). Sixty-nine percent of DES implantations were
or non–FDA-approved indications. Mean follow-up for
MS patients was slightly longer (496  371 days) than for
ES patients (456  302 days), due to the trends in stent
se over the time period studied.
eath. During the 30-month study period, 21,254 deaths
ccurred. Thirty-month overall mortality was higher in
atients who received BMS than DES both before (17.9%
s. 12.9%; p  0.0001) and after adjustment for population
Study Population After Propensity Score Weighting
p Value
DES* BMS*
p Value(n  217,675) (n  45,025)
0.001 42.4 41.7 NS
0.43 30.6 30.7 NS
0.001 39.5 39.8 NS
0.001 9.3 9.7 NS
0.001 63.3 65.6 0.001
36.7 34.4
0.001 85.1 85.4 NS
0.001 14.1 13.8 NS
0.001 0.8 0.8 NS
0.001 38.8 39.2 NS
46.3
55.2
77.5
CABG coronary artery bypass graft surgery; CHF congestive heart failure; DES drug-eluting
descending coronary artery; LCX  left circumflex artery; MI  myocardial infarction; NSTEMI 
coronary artery; STEMI  ST-segment elevation myocardial infarction; UA  unstable angina.tent(s);ifferences (16.5% vs. 13.5%, HR: 0.75; 95% CI: 0.72 to
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Effectiveness of Coronary Stents May 5, 2009:1629–41.79) (Table 2). The adjusted mortality difference was
tatistically significant in the initial 6 months after PCI and
ontinued to increase throughout the 30-month follow-up
eriod (Fig. 2A). The estimated HR obtained with an
nweighted Cox proportional hazards mortality model with
ackward variable selection was similar at 0.79 with a 95%
I (0.76 to 0.81). In addition to the use of DES, other
actors favorably influencing 30-month post-PCI survival
ncluded female sex and prior PCI or CABG. As expected,
ortality was higher in those with diabetes, renal failure,
TEMI, or congestive heart failure.
I. There were 10,528 MIs during the study period.
nadjusted MI rates at 30 months were 10.0 of 100 patients
n BMS versus 7.3 of 100 patients in DES (p  0.0001)
ith similar results after adjustment (8.9 of 100 patients vs.
.5 of 100 patients, HR: 0.77; 95% CI: 0.72 to 0.81) (Table
). This result was driven by lower MI rates in DES patients
uring the first 12 months after PCI (Fig. 2B), with no
ifference between 12 and 30 months of follow-up. In a
econdary analysis, DES patients experienced a small in-
rease in STEMI events beyond 12 months (Fig. 3).
evascularization. Revascularization (PCI or CABG) was
erformed in 34,751 patients, with a total of 40,427
evascularizations; 30-month unadjusted revascularization
ates for BMS and DES populations were 24.5 of 100
atients and 23.0 of 100 patients, respectively (p  0.007).
ith risk-adjustment, no difference in overall revasculariza-
ion was observed in DES versus BMS patients at 30
onths (23.5 of 100 patients vs. 23.4 of 100 patients, HR:
.91; 95% CI: 0.87 to 0.96) (Table 2) (Fig. 2C). However,
evascularization rates were lower in DES patients 12
onths after PCI (13.3 of 100 patients vs. 15.2 of 100
atients), followed by a late rebound in revascularization
rocedures in the DES group between 12 and 30 months
10.2 of 100 patients vs. 8.2 of 100 patients). When CABG
nd PCI revascularizations were examined separately,
ABG was more common in BMS than DES over the
0-month follow-up period (3.7 of 100 patients vs. 2.5 of
Unadjusted and Adjusted Results FromTime-to-Event Analyses for Pre-Specified End Po
Table 2 Unadjusted and Adjusted Results FTime-to-Event Analyses for Pre-Spec
End Point Unadjusted
Death 0.67 (0.65–0.6
Death or MI 0.67 (0.65–0.6
Death or MI or revascularization 0.78 (0.75–0.8
Death or MI or stroke 0.69 (0.67–0.7
MI† 0.66 (0.64–0.7
Revascularization† 0.89 (0.87–0.9
Stroke† 0.90 (0.84–0.9
Bleed† 0.87 (0.81–0.9
NSTEMI† 0.69 (0.66–0.7
STEMI† 0.63 (0.59–0.6
Shown as hazard ratio and 95% confidence interval. *Additional cova
DES, sex, age 75 years, race, diabetes status, renal status, prior reva
and off-label indications. †Patients are censored after death in these
Abbreviations as in Table 1.00 patients), whereas the rate of PCI was similar. ctroke and major bleeding. During follow-up, 4,010
trokes and 5,120 major bleeding events required hospital
tay, with 59% of strokes and 49% of bleeds occurring
ithin 6 months after PCI. Unadjusted and adjusted stroke
ates were roughly 3 of 100 patients at 30 months in each
roup (HR: 0.97; 95% CI: 0.88 to 1.07), and only a minimal
ifference was noted in bleeding (3.6 of 100 patients BMS
s. 3.4 of 100 patients DES, HR: 0.91; 95% CI: 0.84 to
.00) (Table 2) (Figs. 2D and 2E).
omposite end points. Each of the composite end points
racked closely with its individual components, favoring
ES- over BMS-treated patients both before and after
tatistical adjustment (Table 2). The unadjusted 30-month
ates of death or MI (17% vs. 23%), death or MI or
evascularization (32% vs. 38%), and death or MI or stroke
19% vs. 24%) were each lower in DES than BMS patients.
ubgroup analyses. The 30-month DES survival advan-
age was present across all patient subgroups, independent
f sex, age, comorbidities, and procedural indication or
rgency (Fig. 4A). This effect was somewhat less pro-
ounced in those with a prior history of CABG and renal
ailure, with or without dialysis. Notably, patients receiving
ES in 2005 and 2006 had a greater relative survival benefit
han those receiving DES in 2004. Similarly, the 30-month
isk of MI was lower in all patient subgroups except those
ith renal failure and insulin-dependent diabetes (Fig. 4B).
Most patient subgroups experienced a slightly lower
0-month rate of revascularization with DES compared
ith BMS (Fig. 4C). However, no benefit was observed in
atients age 75 years or with diabetes, renal failure, heart
ailure, or 3-vessel disease. Revascularization rates were
imilar in patients undergoing PCI in 2006, in contradis-
inction to the slightly lower DES revascularization rates
rom 2004 and 2005 (Figs. 4D and 4E).
ensitivity analyses. RANDOMIZED TRIAL COHORT. The
9,355 NCDR registry patients fitting the inclusion and
xclusion criteria for the Taxus IV and SIRIUS DES
andomized controlled trials (RCTs) had 30-month out-
End Points
IPW Adjusted IPW  Covariates*
0.76 (0.72–0.79) 0.75 (0.72–0.79)
0.76 (0.72–0.79) 0.75 (0.72–0.79)
0.84 (0.81–0.87) 0.84 (0.81–0.87)
0.77 (0.74–0.81) 0.77 (0.74–0.80)
0.76 (0.72–0.81) 0.77 (0.72–0.81)
0.92 (0.87–0.96) 0.91 (0.87–0.96)
0.98 (0.89–1.07) 0.97 (0.88–1.07)
0.92 (0.85–1.00) 0.91 (0.84–1.00)
0.79 (0.74–0.85) 0.79 (0.74–0.84)
0.74 (0.67–0.81) 0.74 (0.67–0.82)
cluded in the inverse probability weighted  covariates model were:
zations, prior MI, multivessel coronary artery disease, procedure year,
s.ints
rom
ified
9)
8)
0)
0)
0)
2)
8)
3)
3)
8)
riates in
sculariomes similar to those of the overall population such that
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(A) Adjusted cumulative incidence for death with 6- and 12-month landmark display. (B) Adjusted cumulative incidence for myocardial infarction with 6- and 12-month
landmark display. (C) Adjusted cumulative incidence for revascularization with 6- and 12-month landmark display. (D) Adjusted cumulative incidence for bleeding with 6-
and 12-month landmark display. (E) Adjusted cumulative incidence for stroke with 6- and 12-month landmark display. Abbreviations as in Figure 1.
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Effectiveness of Coronary Stents May 5, 2009:1629–41hose receiving DES had a lower 30-month risk of death
HR: 0.62; 95% CI: 0.55 to 0.70), MI (HR: 0.66; 95% CI:
.55 to 0.80), death or MI (HR: 0.64; 95% CI: 0.57 to
.70), and revascularization (HR: 0.87; 95% CI: 0.80 to
.96) compared with BMS. No difference in stroke (HR:
.97; 95% CI: 0.74 to 1.28) or major bleeding (HR: 0.87;
5% CI: 0.71 to 1.05) was noted between trial-eligible DES
nd BMS patients.
AUSE OF DEATH. Presumed “cause” was extrapolated in
9,132 (90%) deaths with the algorithm described in the
receding text and included 8,451 inpatient and 10,591
utpatient deaths. Slightly more BMS deaths were attrib-
table to MI (15.0% vs. 13.5%, p  0.01) and malignancy
6.7% vs. 5.5%, p 0.002), whereas more DES deaths were
ore attributable to chronic lung disease (2.5% vs. 1.9%,
 0.01) and cerebrovascular disease (5.3% vs. 4.2%, p 
.003). No significant differences were found for any of the
emaining diagnoses. Overall, DES patients had a lower risk
f cardiovascular-only (including congestive heart failure
nd MI) deaths compared with BMS patients (HR: 0.80;
5% CI: 0.74 to 0.86) as well as noncardiovascular death
rom all other causes (HR: 0.74; 95% CI: 0.70 to 0.78).
iscussion
ur study is the largest-ever observational comparison of
ong-term outcomes in older patients receiving BMS or
ES. A DES implantation was associated with lower risk of
eath and MI at 30 months as compared with BMS,
hereas there were minor, if any, differences in bleeding,
Figure 3 Adjusted Cumulative Incidence for STEMI
Adjusted cumulative incidence for ST-segment elevation
myocardial infarction (STEMI) with 6- and 12-month landmark display. Abbrevia-
tions as in Figure 1.troke, and overall revascularization. Our methodology al- mowed determination of comparative effectiveness in un-
elected individuals, in contemporaneous DES and BMS
ohorts, with device selection and subsequent management
f patients reflecting real-life, community practice.
re-specified outcomes. DEATH. Prior analyses compar-
ng survival in DES- and BMS-treated patients from
CTs and smaller registries have produced conflicting
esults with relatively low precision. Whereas no differ-
nce in late survival was demonstrated in some RCTs
1,23), registries, and meta-analyses (9 –11,23–28), other
ore recent studies have demonstrated a DES survival
dvantage with a point-estimate similar to that observed in
ur population (13,29–32). The higher annualized mortality
ates for patients in our population receiving either DES or
MS (5.4%/year vs. 6.6%/year) than previously reported in
ome registries (range 1.3%/year to 4.3%/year) (23–27,33,34)
re likely due to higher risk in our elderly, inpatient population
nd are comparable to other Medicare cohorts (11,35).
I. Patients receiving DES experienced a 23% relative
eduction in subsequent MI with no late increase in com-
ined NSTEMI/STEMI risk, a result similar to several
ther analyses (1,9,11). Angiographic assessment of stent
hrombosis was not possible in our dataset; however, iso-
ated analysis of STEMI events revealed a slight increase in
ery late (12 months) STEMI risk in DES patients,
onsistent with prior published reports on late stent throm-
osis (6) and the expected time-course of clopidogrel
iscontinuation (36,37).
EVASCULARIZATION. Although DES have been associated
ith low revascularization rates (6,9,11,13,29–32,34), re-
ent registry reports suggest that they might actually be as
igh as 15% to 19% over a 2- to 3-year follow-up (6,11,26),
ith little difference between DES and BMS patients (6).
he higher rate of repeat revascularization in our population
24%) might be due to not censoring patients after an event
nd to the inability to differentiate target lesion revascular-
zation from nontarget lesion revascularization follow-up
rocedures with claims data. For example, a recent report
rom the Duke database identified a 2-fold higher rate of
verall revascularization versus target vessel revasculariza-
ion in DES patients at 2 years (12.0% vs. 6.6%) (26). Thus,
he lack of anatomic data makes this database less than ideal
or the comparison of revascularization between DES and
MS. An additional concern is the higher rate of late
evascularization in DES compared with BMS, which tends
o obscure the early benefit when examining overall DES-
MS HR. Our revascularization results should be inter-
reted cautiously.
TROKE AND MAJOR BLEEDING. Few differences in stroke or
ajor bleeding rates requiring repeat hospital stay were
bserved between the overall DES and BMS populations.
he anticipated greater use of clopidogrel in the DES group
ight have conferred a bleeding disadvantage, as has been
s
s
e
a
s
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May 5, 2009:1629–41 Effectiveness of Coronary Stentseen in other studies (38,39); however, no statistically
ignificant difference was observed in our population. Un-
Figure 4 Forest Plots of HRs
Subgroup results: Forest plots of hazard ratios (HRs) for death (A), myocardial infa
artery bypass grafting; CHF  congestive heart failure; PCI  percutaneous coronary i
Continued on next page.xpectedly, although a slightly higher unadjusted rate of hnemia-associated deaths was observed in DES patients, no
ignificant adjusted or unadjusted difference in gastrointestinal
(MI) (B), revascularization (C), bleeding (D), and stroke (E). CABG  coronary
tion; RF  renal failure; STEMI  ST-segment elevation myocardial infarction.rction
ntervenemorrhage-associated deaths was evident at 30 months.
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Effectiveness of Coronary Stents May 5, 2009:1629–41egistry versus RCT results: sensitivity analyses. The
ifferences in outcomes between registry and RCT analyses
ave been previously attributed to possible differences in
ES performance in a real-world (registry) population as
Figure 4 Continued
Continued on next pageompared with a restricted RCT population, with the lack sf a survival difference in RCTs being an artifact of their
estricted patient populations. Because creation of a popu-
ation subset fitting the inclusion and exclusion criteria of
he Taxus IV and SIRIUS DES RCTs (20,21) only
harpened the precision for each end point, differences in
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May 5, 2009:1629–41 Effectiveness of Coronary Stentsge, acuity, lesion characteristics, and off-label use in the
egistry and RCT populations are unlikely explanations of
he observed differences in results.
Incomplete risk-adjustment after biased real-world stent
election might also contribute to the survival advantage
oted in this and other registry analyses. Although we used
oth propensity analyses and Cox proportional hazards
odels to adjust for differences in baseline characteristics, it
s possible that unmeasured baseline population differences
emained. In fact, our “cause of death” sensitivity analysis
id show slightly higher rates of death due to malignancy in
MS patients, suggesting that biased patient selection
ight have contributed to the overall mortality result, such
hat “sicker” patients with more comorbid disease received
MS. Although it is possible that the observed differences
etween DES and BMS patients are the sole product of
nmeasured patient selection biases not reflected by this
nalysis, this explanation is less likely, given the large
umber of covariates used in our propensity matching.
tudy strengths. This represents a novel large-scale link-
ge between a national procedural registry and a robust
laims database, demonstrating that nationally representa-
ive analyses are feasible with clinically rich, procedural
egistries and a claims-based structure for follow-up. In
ombination, these 2 resources provide a powerful mecha-
ism for tracking the post-marketing use and outcomes of
ovel devices and procedural innovations, at minimal cost.
mportantly, the project was financed by the Agency for
Figure 4 Continuedealthcare Research and Quality and the Cardiovascular sonsortium of Effective Healthcare Program and was
ndependent of industry.
Data entered in NCDR are intended to be used as a
uality improvement tool and undergo rigorous quality
ontrol (40), whereas the Medicare claims database captures
ll inpatient care episodes. Despite these disparate intents
nd the size and complexity of these 2 databases, our linkage
ate was over 75%, adding to the generalizability of our
esults. We analyzed these data by 3 methods: IPW alone,
PW with Cox proportional hazards modeling, and stan-
ard Cox proportional hazards modeling to compare results
etween the different approaches. The high level of agree-
ent between these methods enhances confidence in our
ndings.
tudy limitations. Our data are observational and there-
ore dependent on the accuracy and completeness of the 2
atched datasets. Reliance on a claims database for out-
omes might be fraught with under-reporting or misclassi-
cation of events. Such misclassification and underreporting
hould be nondifferential, however, and should bias our
stimates toward the null value of no overall difference.
lthough differences in baseline characteristics were rigor-
usly adjusted for using propensity weighting, it is possible
hat additional unadjusted differences between BMS and
ES patients affected results, because our analyses are
imited to the data collected by ACC-NCDR and Medi-
are. Thus we are unable to directly address some important
uestions that have been raised regarding the safety of
tents, including whether repeat revascularization repre-
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Effectiveness of Coronary Stents May 5, 2009:1629–41ented target lesion or vessel restenosis, the incidence of late
tent thrombosis, and the impact of variations in thienopy-
idine use. Although the slight excess of STEMIs in DES
atients after 12 months fits the time course of late stent
hrombosis, these events did not translate to increased late
ortality.
Although the linkage rate of 76% is incomplete, it is
eflective of populations known to be absent from the
edicare data set, such as patients treated at Veterans
dministration facilities, with Medicare Advantage insur-
nce coverage, or undergoing outpatient procedures. Our
ndings are drawn from hospitalized patients over age 65
ears, an age group that accounts for approximately one-half
f all PCIs nationally. Although this cohort is likely sicker
han the generally younger outpatient PCI population, the
imilarity in outcomes in those age 65, 75, and 75 years
uggests that these differences might have been accounted
or in the risk adjustment.
onclusions
n summary, in this large population of Medicare benefi-
iaries undergoing PCI at facilities participating in the
CC-NCDR registry, patients who received DES had
ignificantly lower mortality rates, including an early de-
rease in MI, than those who received BMS. No excess of
ajor bleeding or stroke was noted. The survival advantage
ssociated with DES was maintained across all subgroups
nalyzed and throughout the 30 months of follow-up.
rug-eluting stents seem to be safe and effective in com-
unity practice in the elderly population. Longer follow-up
tudies will need to be conducted to further support these
esults and to confirm the possible effects of antiplatelet
gents.
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APPENDIX
or a supplementary table on the covariates used in the propensity score
odel, please see the online version of this article.
